<DOC>
	<DOCNO>NCT00027820</DOCNO>
	<brief_summary>This phase I/II trial study whether new kind blood stem cell ( bone marrow ) transplant , may less toxic , able treat underlie blood cancer . Stem cell `` seed cell '' necessary make blood cell . Researchers want see use less radiation less chemotherapy new immune suppress drug enable stem cell transplant work . Researchers hop see mixture recipient donor stem cell transplant . This mixture donor recipient stem cell call `` mixed-chimerism '' . Researchers hope see donor cell eliminate tumor cell . This call `` graft-versus-leukemia '' response .</brief_summary>
	<brief_title>Total-Body Irradiation Fludarabine Phosphate Followed Donor Peripheral Blood Stem Cell Transplant Treating Patients With Hematologic Malignancies Kidney Cancer</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine whether stable unrelated peripheral blood stem cell ( PBSC ) graft safely establish use nonmyeloablative pretransplant conditioning intensify post-grafting immunosuppression every ( q ) 8 hour ( hr ) possibly q 6 hr mycophenolate mofetil ( MMF ) dose patient hematologic malignancy renal cell carcinoma . II . To determine incidence severity acute grade II-IV graft-versus-host disease ( GVHD ) reduce patient sustained engraftment use q 8 hr MMF dosing . SECONDARY OBJECTIVES : I . To determine engraftment maintain patient low chimerism high risk rejection use single dose fludarabine ( fludarabine phosphate ) follow donor lymphocyte infusion ( DLI ) continue MMF/cyclosporine ( CSP ) . II . To compare survival disease free survival achieve protocol 1463 . OUTLINE : REDUCED-INTENSITY CONDITIONING : Patients receive fludarabine phosphate intravenously ( IV ) day -4 , -3 , -2 undergo total-body irradiation ( TBI ) day 0 . TRANSPLANT : Patients undergo allogeneic peripheral blood stem cell transplant ( PBSCT ) day 0 . IMMUNOSUPPRESSION : Patients receive cyclosporine orally ( PO ) twice daily ( BID ) day -3 100 taper day 177 mycophenolate mofetil PO every 8 hour day 0-40 taper day 96 . After completion study treatment , patient follow 6 month , 1 year , 1.5 year , 2 year , annually thereafter .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Disease Progression</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Anemia , Refractory</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Chronic</mesh_term>
	<mesh_term>Leukemia , Plasma Cell</mesh_term>
	<mesh_term>Carcinoma , Medullary</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>Ages &gt; 50 year hematologic malignancy treatable unrelated hematopoietic stem cell transplantation ( HSCT ) Ages = &lt; 50 year age hematologic diseases treatable allogeneic HSCT preexist medical condition prior therapy consider high risk regimen relate toxicity associate conventional transplant ( &gt; 40 % risk transplant relate mortality [ TRM ] ) patient refuse conventional HSCT ; transplant must approve inclusion criterion participate institution 's patient review committee Patient Care Conference ( PCC Fred Hutchinson Cancer Research Center [ FHCRC ] ) principal investigator collaborating center ; patient = &lt; 50 year age receive previous autologous transplantation require patient review committee approval ; child &lt; 12 year must discuss FHCRC principal investigator ( PI ) prior registration Patients metastatic renal cell carcinoma histologic subtypes clear cell , papillary medullary may accept regardless age The following disease permit although diagnosis consider approve PCC participate institution 's patient review committee principal investigator : Intermediate high grade nonHodgkin lymphoma ( NHL ) eligible autologous HSCT fail autologous HSCT Low grade NHL &lt; 6 month duration complete remission ( CR ) course conventional therapy Chronic lymphocytic leukemia ( CLL ) must fail two line conventional therapy refractory fludarabine Hodgkin 's disease ( HD ) must receive failed frontline therapy Multiple myeloma ( MM ) must receive prior chemotherapy ; consolidation chemotherapy autografting prior nonmyeloablative HSCT permit Acute myeloid leukemia ( AML ) must &lt; 5 % marrow blast time transplant Acute lymphoblastic leukemia must &lt; 5 % blast time transplant Chronic myelogenous leukemia ( CML ) patient accept chronic phase accelerate phase ; patient receive prior autograft high dose therapy undergone intensive chemotherapy PBSC autologous conventional HSCT advance CML may enrol provide CR chronic phase ( CP ) &lt; 5 % marrow blast time transplant Myelodysplastic syndrome ( MDS ) /myeloproliferative disorder ( MPD ) patient MDS/refractory anemia ( RA ) MDS/refractory anemia ring sideroblast ( RARS ) eligible protocol ; additionally patient myeloproliferative syndrome ( MPS ) eligible ; patient MDS MPS &gt; 5 % marrow blast ( include transformation AML ) must receive cytotoxic chemotherapy achieve &lt; 5 % marrow blast time transplant Renal cell carcinoma must evidence disease amenable surgical cure history active metastatic disease radiological histologic criterion DONOR : FHCRC match allow grade 1.0 2.1 ; unrelated donor prospectively : Matched human leukocyte antigen ( HLA ) A , B , C , DRB1 DQB1 high resolution type Only single allele disparity allow HLAA , B , C define high resolution type DONOR : A positive antidonor cytotoxic crossmatch absolute donor exclusion DONOR : Patient donor pair homozygous mismatch allele consider twoallele mismatch , i.e. , patient A*0101 donor A*0201 , type mismatch allow DONOR : PBSC permit hematopoietic stem cell ( HSC ) source protocol Patients rapidly progressive intermediate high grade NHL Renal cell carcinoma patient : With expect survival le 6 month Disease result severely limited performance status ( &lt; 70 % ) Any vertebral instability History brain metastasis Central nervous system ( CNS ) involvement disease refractory intrathecal chemotherapy Fertile men woman unwilling use contraceptive technique 12 month follow treatment Females pregnant Patients nonhematological tumor except renal cell carcinoma Fungal infection radiological progression receipt amphotericin B active triazole great 1 month Cardiac ejection fraction &lt; 35 % ; ejection fraction require history anthracycline exposure history cardiac disease Diffusion capacity lung carbon monoxide ( DLCO ) &lt; 40 % and/or receive supplementary continuous oxygen The FHCRC PI study must approve enrollment patient pulmonary nodule Patients clinical laboratory evidence liver disease would evaluate cause liver disease , clinical severity term liver function , degree portal hypertension ; patient exclude find fulminant liver failure , cirrhosis liver evidence portal hypertension , alcoholic hepatitis , esophageal varix , history bleed esophageal varix , hepatic encephalopathy , uncorrectable hepatic synthetic dysfunction evince prolongation prothrombin time , ascites related portal hypertension , bacterial fungal liver abscess , biliary obstruction , chronic viral hepatitis total serum bilirubin &gt; 3 mg/dL , symptomatic biliary disease Karnofsky score &lt; 60 ( except renal cell carcinoma [ RCC ] ) Patients &gt; grade II hypertension common toxicity criterion ( CTC ) Human immunodeficiency virus ( HIV ) positive patient The addition cytotoxic agent `` cytoreduction '' exception hydroxyurea imatinib mesylate allow within two week initiation condition DONOR : Marrow donor DONOR : Donors HIVpositive and/or , medical condition would result increase risk filgrastim ( GCSF ) mobilization harvest PBSC</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>